Scope 3 emissions, covering the entire value chain, account for up to 75% of a pharma company's ghg emissions, necessitating sustainable practices in r&d, manufacturing, and sourcing This review also evaluates and highlights current developments in green chemistry technologies that are especially appropriate for pharmaceutical synthesis Advances in green chemistry technologies, such as continuous reactions, enzyme catalysis and synthetic biology, are paving the way for more sustainable drug synthesis These technologies have demonstrated wide applications in production, indicating a promising future for green chemistry in pharmaceutical manufacturing. Green pharma companies aim to change this by using cleaner methods They might employ technologies that reduce reliance on toxic solvents or design systems that recycle these materials during production
Innovations like biocatalysis are also helping make the manufacturing process greener Biocatalysis uses natural enzymes to help create drugs. Green synthesis methods for apis no doubt represent a transformative opportunity for the pharmaceutical industry The future of green chemistry in pharmaceutical manufacturing is filled with promising developments Ai and machine learning in optimizing green synthesis advanced algorithms are being used to design efficient synthetic routes, predict reaction outcomes, and identify greener alternatives—accelerating sustainable innovation at scale. The move to digital transformation represents a true paradigm shift in manufacturing, enabling organizations to leverage advanced technologies such as the industrial internet of things (iiot), cloud computing, and artificial intelligence (ai) to ensure compliance and secure a competitive advantage
This article explores how fda gmp guidelines align with sustainable practices, focusing on waste reduction, energy efficiency, and the adoption of green technologies in pharmaceutical manufacturing. These practices not only mitigate environmental damage but also.
OPEN
